Literature DB >> 27007092

The relevance of preoperative ultrasound cervical mapping in patients with thyroid cancer.

Davit Kocharyan1, Frank Schwenter1, Manon Bélair1, Edgard Nassif1.   

Abstract

BACKGROUND: Cervical lymph node involvement in thyroid cancer is associated with locoregional recurrence and decreased disease-free survival. Preoperative lymph node mapping helps in planning surgery for neck dissection and improves patient outcomes. We sought to perform a qualitative and quantitative analysis of ultrasound mapping for thyroid cancer and evaluate the clinical importance of this exam in terms of identifying the group of patients who would benefit most from subsequent surgical dissection.
METHODS: We retrospectively reviewed the cases of 263 patients who underwent thyroid surgery between 2009 and 2013. We calculated the positive predictive values (PPVs) of ultrasound mapping of both the lateral and central compartments together and the lateral or central compartment individually. A quantitative analysis was performed by comparing the number of positive lymph nodes at ultrasound imaging with histopathologic evaluation.
RESULTS: A total of 136 cases of thyroid cancer in 120 patients met the inclusion criteria for ultrasound mapping analysis. The PPVs (and 95% confidence intervals) were 83.82 (0.76-0.89) for the lateral and central compartments, 85.39% (0.76-0.91) for the lateral compartment, and 80.48% (0.7-0.87) for the central compartment. When comparing the positive lymph nodes at ultrasound imaging with histopathologic evaluation, the result was χ(2) = 10.33 (p = 0.006).
CONCLUSION: This single-institution study indicated that preoperative ultrasound mapping is an accurate imaging procedure for predicting lymphatic spread in differentiated and medullary thyroid cancer. Ultrasound mapping can be used as an efficient tool for surgical planning and prognosis determination, as well as for identifying the group of patients who would benefit most from subsequent surgical intervention.

Entities:  

Mesh:

Year:  2016        PMID: 27007092      PMCID: PMC4814284          DOI: 10.1503/cjs.011015

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  31 in total

1.  Preoperative neck ultrasonographic mapping for persistent/recurrent papillary thyroid cancer.

Authors:  Hussam M Binyousef; Ali S Alzahrani; Saif S Al-Sobhi; Suhaibani Hamed S Al; Mohammed A Chaudhari; Hussain M Raef
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

2.  Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma.

Authors:  Pedro Weslley Souza Rosário; Sérgio de Faria; Luciano Bicalho; Maria Flávia Gatti Alves; Michelle Aparecida Ribeiro Borges; Saulo Purisch; Eduardo Lanza Padrão; Leonardo Lamego Rezende; Alvaro Luís Barroso
Journal:  J Ultrasound Med       Date:  2005-10       Impact factor: 2.153

3.  Same-day ultrasound guidance in reoperation for locally recurrent papillary thyroid cancer.

Authors:  Kelly L McCoy; John H Yim; Mitchell E Tublin; Lynn A Burmeister; Jennifer B Ogilvie; Sally E Carty
Journal:  Surgery       Date:  2007-12       Impact factor: 3.982

Review 4.  Management of thyroid nodules and surgery for differentiated thyroid cancer.

Authors:  N G Iyer; A R Shaha
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-04-08       Impact factor: 4.126

5.  Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer.

Authors:  John M Stulak; Clive S Grant; David R Farley; Geoffrey B Thompson; Jon A van Heerden; Ian D Hay; Carl C Reading; J William Charboneau
Journal:  Arch Surg       Date:  2006-05

Review 6.  Preoperative detection of cervical lymph node metastases in papillary thyroid cancer: a surgical perspective.

Authors:  George H Sakorafas; Spiros Christodoulou; Christos Lappas; Michael Safioleas
Journal:  Onkologie       Date:  2009-11-20

7.  Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features.

Authors:  Kyung-Eun Kim; Eun-Kyung Kim; Jung Hyun Yoon; Kyung Hwa Han; Hee Jung Moon; Jin Young Kwak
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

8.  Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography.

Authors:  Iwao Sugitani; Yoshihide Fujimoto; Keiko Yamada; Noriko Yamamoto
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

Review 9.  Developments in the use of ultrasound for thyroid cancer.

Authors:  John I Lew; Steven E Rodgers; Carmen C Solorzano
Journal:  Curr Opin Oncol       Date:  2010-01       Impact factor: 3.645

Review 10.  Imaging for staging and management of thyroid cancer.

Authors:  Ann D King
Journal:  Cancer Imaging       Date:  2008-03-25       Impact factor: 3.909

View more
  3 in total

1.  The Role of Calcitonin in Predicting the Extent of Surgery in Medullary Thyroid Carcinoma: A Nationwide Population-Based Study in Norway.

Authors:  Else Marie Opsahl; Lars Andreas Akslen; Ellen Schlichting; Turid Aas; Katrin Brauckhoff; Anne Irene Hagen; Alf Frimann Rosenlund; Eva Sigstad; Krystyna K Grøholt; Lars H Jørgensen; Trine Bjøro
Journal:  Eur Thyroid J       Date:  2019-04-29

2.  Lymph Node Metastasis and Extrathyroidal Extension in Papillary Thyroid Microcarcinoma in Cyprus: Suspicious Subcentimeter Nodules Should Undergo FNA When Multifocality is Suspected.

Authors:  Christos Papaioannou; Demetris Lamnisos; Katerina Kyriacou; Theodoros Lyssiotis; Vasilis Constantinides; Savvas Frangos; Aliki Economides; Panayiotis A Economides
Journal:  J Thyroid Res       Date:  2020-03-24

3.  Medullary Thyroid Carcinoma: Do Ultrasonography and F-DOPA-PET-CT Influence the Initial Surgical Strategy?

Authors:  Lindsay Brammen; Martin B Niederle; Philipp Riss; Christian Scheuba; Andreas Selberherr; Georgios Karanikas; Gerd Bodner; Oskar Koperek; Bruno Niederle
Journal:  Ann Surg Oncol       Date:  2018-10-10       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.